HS-20118 clinical trials
Also written HS-20118.
How each study uses HS-20118 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the HS-20118 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- HS-20118
- 4
Studies by the year they started
4 studies that test it; most in 2025 (2)
| Year | Studies |
|---|---|
| 2025 | 2 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test HS-20118.
- Dec 2026A Study to Evaluate the Pharmacokinetic Characteristics of HS-20118 Under Different Dosing Conditions in Healthy ParticipantsPhase 1 · Jiangsu Hansoh Pharmaceutical Co., Ltd.
- Feb 2027A Phase 2 Study of HS-20118 to Evaluate the Efficacy and Safety in Participant With Moderate-to-Severe Plaque PsoriasisPhase 2 · Jiangsu Hansoh Pharmaceutical Co., Ltd.
Studies
Open first, then newest update. How each study uses HS-20118 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- A Phase 2 Study of HS-20118 to Evaluate the Efficacy and Safety in Participant With Moderate-to-Severe Plaque PsoriasisNot yet recruitingPhase 2Jiangsu Hansoh Pharmaceutical Co., Ltd.NCT07765628Written as HS-20118
- Evaluate the Safety and Pharmacokinetics/Pharmacodynamics and Food Effect of HS-20118RecruitingPhase 1Jiangsu Hansoh Pharmaceutical Co., Ltd.NCT07033234Written as HS-20118
- Evaluate the Safety and Pharmacokinetics/Pharmacodynamics of HS-20118CompletedPhase 1Jiangsu Hansoh Pharmaceutical Co., Ltd.NCT06846710Written as HS-20118
- A Study to Evaluate the Pharmacokinetic Characteristics of HS-20118 Under Different Dosing Conditions in Healthy ParticipantsActive, not recruitingPhase 1Jiangsu Hansoh Pharmaceutical Co., Ltd.NCT07896915Written as HS-20118
What changed recently
From the registry's own updates since Oct 18, 2026.